PRESS RELEASEREGULATED INFORMATION10 March 2022, 18:00 CET Ghent, Belgium, 10 March 2022 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an
PRESS RELEASEREGULATED INFORMATION21 January 2022, 06:00 pm CET Ghent, Belgium - 21 January 2022 - Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"),
Sequana Medical NV: SEQUANA MEDICAL S NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
Ghent, Belgium, 16 February 2021 - Sequana Medical NV
(Euronext Brussels: SEQUA) (the
Sequana
Medical ), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces, in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context of the capital increase that was announced on 9 February and completed on 15 February 2021 by means of a private placement through an accelerated bookbuilding procedure, its share capital has increased from EUR 1,635,006.12 to EUR 1,909,241.43 and the number of issued and outstanding shares has increased from 15,778,566 to 18,425,625 ordinary shares, through the issuance of a total of 2,647,059 new shares.